Why Dynavax Technologies Corporation Stock Is Rising Today

Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) are up by over 11% in pre-market trading on modest volume this morning, following a report that management is exploring different strategic options for its hepatitis B vaccine, Heplisav-B, including a licensing deal or an outright sale.

Image source: Getty Images.

After receiving a positive advisory committee vote earlier this year, Heplisav-B is now widely expected to get the green light from the FDA in the next few weeks. If that line holds, the vaccine should be on the market in early 2018.

Source: Fool.com